SecBot SecBot
SECBOTREPLAY Home › Report › PFE

PFE · Pfizer reaffirms full-year 2026 guidance following the CFO transition…

PFIZER INC · 8-K filed Jun 18, 2026 at 13:17 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 18, 2026 at 13:17 ET

Pfizer reaffirms full-year 2026 guidance following the CFO transition announcement on June 18, 2026. Revenue guidance remains $59.5-$62.5B and adjusted diluted EPS at $2.80-$3.00, unchanged from prior communication. This is a routine confirmation filing with no new material financial data.

  • FY2026 revenue guidance reaffirmed at $59.5-$62.5B
  • FY2026 adjusted diluted EPS guidance reaffirmed at $2.80-$3.00
  • CFO transition announced on June 18, 2026, prompted this reaffirmation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access